WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2021
January 21, 2021 at 06:26 am EST
Share
WuXi AppTec Co., Ltd. provided earnings guidance for the year ended December 31, 2021. The net profit attributable to shareholders of the Company was estimated to increase, by a range between RMB927.2755 million to RMB1,112.7306 million for the year of 2020 as compared with RMB1,854.5509 million for the year of 2019, representing a year-over-year increase of a range between 50% to 60%. The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss was estimated to increase by a range between RMB382.8567 million to RMB478.5708 million for the year of 2020, as compared with 1,914.2833 million for the year of 2019, representing a year-over-year increase of a range between 20% to 25%. The adjusted non-IFRS net profit attributable to shareholders of the company was estimated to increase by a range between RMB1,083.3416 million to RMB1,203.7129 million for the year of 2020, as compared with RMB2,407.4257 million for the year of 2019, representing a year-over-year increase of a range between 45% to 50%.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .